What is the black box warning for raloxifene?

What is the black box warning for raloxifene?

Black box warnings were added to the label of raloxifene in 2007 warning of increased risk of death due to stroke for postmenopausal women with documented coronary heart disease or at increased risk for major coronary events, as well as increased risk for deep vein thrombosis and pulmonary embolism.

What class drug is raloxifene?

Raloxifene is in a class of medications called selective estrogen receptor modulators (SERMs). Raloxifene prevents and treats osteoporosis by mimicking the effects of estrogen (a female hormone produced by the body) to increase the density (thickness) of bone.

Is raloxifene FDA approved for osteoporosis?

Today, Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved its osteoporosis drug EVISTA(R) (raloxifene HCl) for a new use to reduce the risk of invasive breast cancer in two populations: postmenopausal women with osteoporosis and postmenopausal women at high risk …

Is raloxifene safer than Tamoxifen?

This means that raloxifene reduces risk of non-invasive breast cancer by about 38 percent compared to tamoxifen reducing risk for this type of cancer by about 50 percent; or raloxifene is about 78 percent as effective as tamoxifen in reducing the risk of noninvasive breast cancer over almost 7 years.

Is raloxifene banned?

Raloxifene is one of the selective estrogen receptor modulators and is often used to prevent and treat osteoporosis in postmenopausal women. Because of the indirect impact on serum testosterone levels and the potential ability for performance enhancement, it is banned by the World Anti-Doping Agency (WADA).

Is raloxifene an immunosuppressant?

Decreased levels of mRNA for both tumor necrosis factor alpha and RANKL in spleen cells from raloxifene-treated arthritic mice indicated an immunosuppressive action of this SERM.

What does a raloxifene tablet look like?

raloxifene 60 mg tablet This medicine is a white, oval, film-coated, tablet imprinted with “393”.

How long should you be on raloxifene?

Background: Due to the chronic nature of osteoporosis and the risk of invasive breast cancer, raloxifene 60 mg/day (raloxifene) is intended to be used for long-term treatment (treatment >3 years).

What are contraindications of raloxifene?

Contraindications to raloxifene include past medical history of deep venous thrombosis, renal vein thrombosis, pulmonary embolism, malignancy, active smoking, or any thrombophilia (factor V Leiden deficiency, prothrombin gene mutation G20210A, antiphospholipid syndrome, deficiency of antithrombin, protein c and s …

Who should not use raloxifene?

14 embolism) have been reported with EVISTA. Women who have or have had blood clots 15 in the legs, lungs, or eyes should not take EVISTA. 16 • Women who have had a heart attack or are at risk for a heart attack may have an 17 increased risk of dying from stroke when taking EVISTA. 1.

What is Raloxifene hydrochloride used for?

FDA label information for this drug is available at DailyMed. Raloxifene hydrochloride is approved to prevent: Breast cancer. It is used to decrease the chance of invasive breast cancer in postmenopausal women who have a high risk for developing the disease or who have osteoporosis. Raloxifene hydrochloride is also approved to prevent and treat:

Can women take Raloxifene hydrochloride tablets?

Women who have had a heart attack or are at risk for a heart attack may have an increased risk of dying from stroke when taking raloxifene hydrochloride tablets. 1.

What is the empirical formula of raloxifene hydrochloride?

Raloxifene hydrochloride (HCl) has the empirical formula C28H27NO4S•HCl, which corresponds to a molecular weight of 510.05. Raloxifene HCl, USP is an off-white to pale-yellow solid that is very slightly soluble in water. Raloxifene hydrochloride tablets, USP are supplied in a tablet dosage form for oral administration.

Can raloxifene be used to treat breast cancer?

Raloxifene cannot be used to treat invasive breast cancer or to prevent invasive breast cancer from coming back in women who have already had the condition. Raloxifene also cannot be used to decrease the risk of developing noninvasive breast cancer.